| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 06/01/2005 | CN1621066A Medicine for treating cholecystitis |
| 06/01/2005 | CN1621062A Chinese traditional medicinal injection for treating chronic hepatitis |
| 06/01/2005 | CN1621061A Chinese traditional medicine for treating chronic gall bladder disease |
| 06/01/2005 | CN1621058A Chinese traditional medicine for preventing and treating biliary tract inflammation and its preparation process |
| 06/01/2005 | CN1621054A Pure Chinese traditional medicine for treating stomach and duodenum ulcer |
| 06/01/2005 | CN1621053A Medicine for treating hepatitis B |
| 06/01/2005 | CN1621043A Powder injection preparation of diammonium glycyrrhizinate and its preparation |
| 06/01/2005 | CN1621040A Antemetic Granisetron Hydrochloride tablet and its preparation |
| 06/01/2005 | CN1621036A Powder injection of hydrochloric acid ranitidine and its preparation method |
| 06/01/2005 | CN1620886A Ice-cream for preventing decayed tooth |
| 06/01/2005 | CN1204249C Kelp sugar-releasing enzyme, preparation and application of the same |
| 06/01/2005 | CN1204138C Pyrazolo [4, 3-d] pyrimidine derivs. |
| 06/01/2005 | CN1204134C Sulfamine-substituted benzodihydopyran, preparation method, use as medicine or diagnostic reagent and medicine containing same |
| 06/01/2005 | CN1203892C Aqueous solution formulation of alpha-interferon |
| 06/01/2005 | CN1203883C Medicine for treating liver cirrhosis |
| 06/01/2005 | CN1203875C Chinese herbal lozenge for treating laryngopharyngitis and its preparation method |
| 06/01/2005 | CN1203872C Medicine for treating chronic colitis |
| 06/01/2005 | CN1203871C Medicine for treating diseases of digestive system |
| 06/01/2005 | CN1203869C Technique for preparing granules of toad oil |
| 06/01/2005 | CN1203864C Spray formulation of providone iodine |
| 06/01/2005 | CN1203863C Use of pet food compositions containing fermentable fiber |
| 06/01/2005 | CN1203859C Medicine for curing toothache |
| 06/01/2005 | CN1203852C Valdecoxib compositions |
| 06/01/2005 | CN1203851C Use of inhibitor produced or released by reactive oxygen metablite in producing pharmaceutical |
| 06/01/2005 | CN1203838C Desensitizing dentifrice containing potassium and tin salts |
| 05/31/2005 | US6900344 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 05/31/2005 | US6900338 Scavenger compounds |
| 05/31/2005 | US6900336 8-aza-11-deoxy prostaglandin analogues |
| 05/31/2005 | US6900334 Antiallergens; autoimmune diseases |
| 05/31/2005 | US6900318 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 05/31/2005 | US6900309 Aminocarbonylation reaction of a adenosine compound containing purine base and pentofuranosyl sugar and a leaving group at 2 position of purine ring, with an amine compound in presence of carbon monoxide and suitable coupling catalyst |
| 05/31/2005 | US6900243 Phenylheteroalkylamine derivatives |
| 05/31/2005 | US6900242 Compound for use in the treatment of cancer and prevention of infections |
| 05/31/2005 | US6900226 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/31/2005 | US6900222 Relaxant drugs; antiulcer agents |
| 05/31/2005 | US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants |
| 05/31/2005 | US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 05/31/2005 | US6900212 Anxiolytic agents; psychological disorders; sexual disorders; eating disorders |
| 05/31/2005 | US6900211 CCR5 antagonists useful for treating aids |
| 05/31/2005 | US6900202 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders |
| 05/31/2005 | US6900201 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/31/2005 | US6900200 Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists |
| 05/31/2005 | US6900043 Phosphatases which activate map kinase pathways |
| 05/31/2005 | US6899879 Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies |
| 05/26/2005 | WO2005046358A1 Method of using whole olive and food having activity against helicobacter pylori |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113418 Improving the inhibition of gastric acid secretion in the treatment of a gastrointestinal disorder by the oral administration of a an acid labile H+, K+-ATPase inhibitor by administering two or more consecutive oral unit dose with 0.5-4 hour intervals; antisecretory, antiulcer agents, e.g., omeprazole |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 05/26/2005 | US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders |
| 05/26/2005 | US20050113333 Comprises caffeic acid, chlorogenic acid, and/or ferulic acid, water-soluble and fermentable dietary fiber (alginate, polydextrose) |
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050113284 Drug for regenerating tissue and vessel and method therefor |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112144 Deactivated, cell-free; culture product using protease; harvesting; separation |
| 05/26/2005 | US20050112114 Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| 05/26/2005 | CA2544308A1 Cytokine antagonist molecules |
| 05/26/2005 | CA2543582A1 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 05/25/2005 | EP1533294A1 Beta-alanine derivative and use thereof |
| 05/25/2005 | EP1532250A1 Fcyriia transgenic animal model for autoimmune disease |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 05/25/2005 | EP1532157A2 Novel phosphonic acid based prodrugs of pmea and its analogues |
| 05/25/2005 | EP1532144A1 Novel quinuclidine derivatives and their use |
| 05/25/2005 | EP1532135A1 Nf-kb inhibitors |
| 05/25/2005 | EP1532133A1 Nf-:b inhibitors |
| 05/25/2005 | EP1532131A2 Motilide compounds |
| 05/25/2005 | EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 05/25/2005 | EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid |
| 05/25/2005 | EP1532108A2 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 05/25/2005 | EP1532105A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 05/25/2005 | EP1531857A1 Metalloproteinase inhibitors |
| 05/25/2005 | EP1531847A2 Pharmaceutical formulation |
| 05/25/2005 | EP1531841A1 Probiotics for gut neuromuscular functions |
| 05/25/2005 | EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 05/25/2005 | EP1531834A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| 05/25/2005 | EP1531833A1 Antisense compounds, methods and compositions for treating mmp-12 related inflammatory disorders |
| 05/25/2005 | EP1531832A1 Therapeutic compositions for use in prophylaxis or treatment of diarrheas |
| 05/25/2005 | EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 05/25/2005 | EP1531825A2 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| 05/25/2005 | EP1531815A1 Glucokinase activators |
| 05/25/2005 | EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 05/25/2005 | EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 05/25/2005 | EP1531801A1 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 05/25/2005 | EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 05/25/2005 | EP1531684A1 Method for controlling hairballs |
| 05/25/2005 | EP1531676A2 Compositions and methods for liver growth and liver protection |
| 05/25/2005 | EP1408944B1 Erucamide compounds for the treatment and prevention of disturbances of the secretory system |
| 05/25/2005 | EP1341791B1 Thioether substituted imidazoquinolines |
| 05/25/2005 | EP1100481B1 Pharmaceutical formulations comprising beclomethasone dipropionate for the treatment of inflammatory bowel disease |
| 05/25/2005 | EP1039911B1 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS |